Pharmacogenomics articles within Nature Communications

Featured

  • Comment
    | Open Access

    Innovative pharmacogenomic approaches (genetic variation related to medication response) are needed to reduce disease and disparities in Indigenous communities. We support community-based pharmacogenomics research, inclusive of Indigenous values and priorities, to improve the health and well-being of Indigenous peoples.

    • Katrina G. Claw
    • , Casey R. Dorr
    •  & Erica L. Woodahl

  • Article
    | Open Access

    Clinically significant genetic variation in Asian populations is under-characterized. Here, the authors show the diversity in prevalence and spectrum of human disease and pharmacogenetic variants in a multi-ethnic Asian population.

    • Sock Hoai Chan
    • , Yasmin Bylstra
    •  & Weng Khong Lim

  • Article
    | Open Access

    Statins are promising for breast cancer therapy; dipyridamole can potentiate their effects, but is contraindicated in some cases. Here, the authors develop a pharmacogenomics pipeline to predict other compounds that potentiate statins, and validate the top candidates in cell line screens and 3D cultures.

    • Jenna E. van Leeuwen
    • , Wail Ba-Alawi
    •  & Deena M. A. Gendoo

  • Article
    | Open Access

    To try to predict an individual’s drug response using genetic data, most studies have used traditional polygenic risk score (PRS) methods. Here, the authors develop a pharmacogenomics-specific PRS method, which can improve drug response prediction and patient stratification in pharmacogenomics studies.

    • Song Zhai
    • , Hong Zhang
    •  & Judong Shen

  • Article
    | Open Access

    Mutational signatures can reveal the impact of mutagenic processes in cancer, including exposure to therapy. Here, the authors develop an approach that can accurately predict drug responses in cancer using mutational signatures while simultaneously correcting for germline variants with an ancestry matching procedure.

    • Jurica Levatić
    • , Marina Salvadores
    •  & Fran Supek

  • Article
    | Open Access

    Adverse drug reactions are an important clinical problem. Here the authors combine information about drug-induced gene expression changes and genetic variability of patients with a genome-scale metabolic model to identify drug-induced changes in cellular metabolism that may be linked to drug side effects.

    • Daniel C. Zielinski
    • , Fabian V. Filipp
    •  & Bernhard O. Palsson

Browse broader subjects

Browse Pharmacogenomics across other nature.com journals